Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Cardinal Health Unveils Two Distribution Centers in Central Ohio
Cardinal Health announced has that it is celebrating the opening of two new distribution centers […]
Premier Research Fortifies Cell and Gene Therapy Leadership Team
Premier Research announced today the addition of Kenneth Ndugga-Kabuye, M.D., FACMG, as VP, Cell & […]
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
Acadia Pharmaceuticals today announced that DAYBUE™ (trofinetide) is now available for the treatment of Rett […]
Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023
Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, announced […]
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Genmab and argenx announced today that they have entered into a collaboration agreement to jointly […]
Otsuka and Lundbeck Issue Statement on FDA Advisory Committee Meeting on REXULTI® for the Treatment of Agitation Associated with Alzheimer’s Dementia
Otsuka Pharmaceutical and Lundbeck Pharmaceuticals announce the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee […]
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease
AbbVie has announced the European Commission (EC) approved RINVOQ (upadacitinib, 45 mg [induction dose] and 15 […]
Sapience Therapeutics to Present Late-Breaking Data on ST101 and ST316 at the American Association for Cancer Research (AACR)
Sapience Therapeutics, a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics […]
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
Telix Pharmaceuticals today announces the successful preclinical development of radiolabelled olaratumab, an antibody licensed from […]
WuXi Biologics and WuXi XDC Congratulate DualityBio on Entering Global Licensing and Collaboration Agreements with BioNTech
WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) and its subsidiary […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more